QBIO — Q BioMed Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $9.25m
- $0.28m
Annual income statement for Q BioMed, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2018 November 30th | 2019 November 30th | 2020 November 30th | 2021 November 30th | 2022 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.03 | 0.196 | 0.284 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -0.296 | -0.051 | -0.009 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.02 | 8.61 | 13.2 | 7.63 | 0.984 |
| Operating Profit | -9.02 | -8.61 | -13.2 | -7.43 | -0.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.27 | -10.3 | -13.5 | -8.24 | -2.05 |
| Net Income After Taxes | -9.27 | -10.3 | -13.5 | -8.24 | -2.05 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.27 | -10.3 | -13.5 | -8.24 | -2.05 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.27 | -10.3 | -14.4 | -8.74 | -3.49 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.675 | -0.644 | -0.646 | -0.325 | -0.139 |